The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc. (NASDAQ : OCUL) securities between March 10, 2016 and July 6, 2017.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Ocular Therapeutix, Inc. you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.